Women’s Hormone Health: The Complete Guide for 2026

What Is Women’s Hormone Therapy?

Women’s hormone therapy encompasses a broad range of treatments targeting the hypothalamic-pituitary-ovarian (HPO) axis. Estrogen and progesterone are the primary ovarian hormones, governing the menstrual cycle, bone metabolism, cardiovascular protection, neurocognition, and reproductive function. When ovarian function declines—whether through natural menopause, surgical oophorectomy, premature ovarian insufficiency, or hypothalamic amenorrhea—replacement of these hormones can restore quality of life and prevent long-term health consequences.

Bioidentical hormones are molecularly identical to endogenous human hormones. Estradiol (17-beta estradiol) is the primary estrogen, available as oral tablets, transdermal patches, topical gels, vaginal rings, and injectable esters. Micronized progesterone (Prometrium®) is the bioidentical form of progesterone, preferred over synthetic progestins for its superior safety profile, sleep-promoting effects, and neuroprotective properties.

Fertility medicine represents another major branch, using gonadotropins (FSH, HMG), GnRH agonists and antagonists, and ovulation-inducing agents like letrozole and clomiphene to achieve and maintain pregnancy. Anti-androgen therapy with spironolactone addresses conditions like polycystic ovary syndrome (PCOS), hormonal acne, and female-pattern hair loss. Each of these interventions requires careful monitoring, dose titration, and individualized management.

Women’s Health Compound Library

Estrogen Formulations

Progesterone

Fertility Medications

GnRH Agonists & Antagonists

Anti-Androgens & Other

Common Protocols

Menopausal hormone therapy (MHT) follows the principle of using the lowest effective dose for the shortest necessary duration, though many women remain on therapy for years or decades with good outcomes. Transdermal estradiol at 0.025–0.1 mg/day (patch) or 0.5–1.5 mg/day (gel) is preferred over oral forms because it avoids hepatic first-pass metabolism, reducing VTE risk. Micronized progesterone at 100–200 mg nightly is used cyclically (12–14 days per month) or continuously for endometrial protection in women with a uterus.

IVF stimulation protocols typically begin with FSH (150–450 IU daily) or FSH/HMG combinations starting cycle day 2–3. A GnRH antagonist (cetrorelix or ganirelix 0.25 mg daily) is added when the lead follicle reaches 13–14 mm to prevent premature LH surge. The hCG trigger (Ovidrel 250 mcg) is administered when two or more follicles reach 17–18 mm. Egg retrieval occurs 34–36 hours post-trigger. Luteal support with progesterone in oil (50 mg IM daily) or vaginal progesterone begins the day after retrieval.

Letrozole for ovulation induction in PCOS is dosed at 2.5–7.5 mg daily for 5 days starting cycle day 3–5. Clomiphene follows a similar pattern at 50–150 mg daily. Monitoring with transvaginal ultrasound and estradiol levels guides dose adjustments and trigger timing.

Spironolactone for anti-androgen therapy is dosed at 50–200 mg daily, typically requiring 3–6 months for visible skin and hair improvements. Reliable contraception is mandatory due to teratogenicity. Potassium levels should be checked within the first month and monitored quarterly. For women who cannot tolerate systemic spironolactone, topical formulations (5% cream) offer localized anti-androgen effects.

Who Should Consider This?

Perimenopausal and menopausal women experiencing hot flashes, night sweats, vaginal dryness, mood changes, sleep disruption, or accelerated bone loss are candidates for MHT. The “timing hypothesis” supports initiating HRT within 10 years of menopause onset or before age 60 for maximum cardiovascular and cognitive benefit. Women with premature ovarian insufficiency (menopause before 40) should receive HRT at minimum until the average age of natural menopause (51) to prevent osteoporosis and cardiovascular disease.

Women with PCOS, unexplained infertility, diminished ovarian reserve, or hypothalamic amenorrhea benefit from targeted fertility medications. Those with androgen-driven skin conditions (hormonal acne, hirsutism) may find relief with spironolactone. Contraindications include active or recent breast cancer, active liver disease, unexplained vaginal bleeding, and history of estrogen-dependent blood clots (for systemic estrogen). Individual risk assessment should guide every treatment decision.

Monitoring & Safety

Baseline bloodwork for MHT includes estradiol, progesterone, FSH, LH, SHBG, total and free testosterone, DHEA-S, thyroid panel (TSH, free T3, free T4), CBC, CMP, lipid panel, and fasting insulin. Follow-up labs at 6–8 weeks and then every 6–12 months. Target estradiol on transdermal HRT is typically 50–150 pg/mL for symptom relief without excessive levels.

During IVF stimulation, transvaginal ultrasound every 1–3 days monitors follicle count and size. Estradiol levels guide dose adjustments—rapid rises above 3,000–4,000 pg/mL increase ovarian hyperstimulation syndrome (OHSS) risk. Anti-Müllerian hormone (AMH) and antral follicle count (AFC) at baseline help predict ovarian response and guide starting doses.

Women on spironolactone need baseline and follow-up potassium and renal function tests. Annual mammography and cervical screening should continue per standard guidelines. Report any unexpected bleeding on HRT, breast lumps, severe headaches, or vision changes to your physician immediately. DEXA scans every 1–2 years track bone density in postmenopausal women, especially those at risk for osteoporosis.

Frequently Asked Questions

Does HRT increase breast cancer risk?

The WHI data showed a modest increased risk (8 additional cases per 10,000 women-years) with combined estrogen-progestin therapy using synthetic progestin (medroxyprogesterone). Estrogen-alone therapy in women without a uterus actually showed decreased breast cancer risk. Bioidentical micronized progesterone appears to carry a lower risk than synthetic progestins. The absolute risk increase is comparable to regular alcohol consumption or obesity. Individual risk assessment using tools like the Gail Model helps guide decisions.

How long can I stay on hormone therapy?

The old recommendation of “lowest dose, shortest duration” has been replaced by individualized risk-benefit assessment. Many women remain on HRT for decades with ongoing physician monitoring. The North American Menopause Society (NAMS) no longer recommends arbitrary time limits. Benefits including bone protection, cardiovascular health, and quality of life often outweigh risks when therapy is initiated within the timing window and monitored appropriately.

Is bioidentical better than synthetic?

Bioidentical hormones (estradiol, micronized progesterone) are molecularly identical to human hormones and generally have more favorable safety profiles than synthetic versions (conjugated equine estrogens, medroxyprogesterone). Transdermal estradiol avoids the clotting factor increases seen with oral estrogens. FDA-approved bioidentical options exist (Estrace, Vivelle-Dot, Prometrium), and compounded formulations offer additional dosing flexibility under pharmacist supervision.

What if I had early menopause?

Women with premature ovarian insufficiency (POI) or surgical menopause before age 40–45 have a clear indication for HRT. Without estrogen replacement, these women face accelerated bone loss (up to 3–5% per year), increased cardiovascular risk, cognitive decline, and urogenital atrophy. HRT should continue at minimum until age 50–51, with many experts recommending indefinite therapy. Higher replacement doses may be needed compared to natural menopause given the more abrupt hormonal decline.